Future studies should evaluate these molecules in larger canine patient cohorts, as well as determine the effects of TAZ and YAP knockdown and/or pharmacologic targeting of these transcription factors as well as TGFβ, on additional traits of OSA progression. The gene discussed is WWTR1; the disease is obstructive sleep apnea syndrome.